The trajectory of Sildenafil presents a complex picture for shareholders. While the initial launch generated significant gains, the expiration of its intellectual property protection opened the door to generic versions, dramatically diminishing revenue. This presents a specific risk for firms depending on comparable blockbuster offerings, suggestin

The story of Viagra, and its parent company copyright, presents a complex case study for investors. At first a blockbuster drug, yielding billions in revenue , its patent expiration created a flood of generic competition , significantly impacting its position . While some pharmaceutical companies may attempt to capitalize on similar conditions , th